Kirn David sold $19K of FDMT
Kirn David (See Remarks) sold 1,922 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $10.02 on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a datapoint on insider ownership changes but does not include new company-specific fundamentals or catalysts.
Market read
Insider selling under 10b5-1 is typically a low-signal event; expect limited trading impact absent other news.
What to watch
Traders should check whether the insider has a pattern of sales/buys and whether other contemporaneous disclosures (financing, trial updates) exist—none are provided here.
Background
The article is an SEC Form 4 insider transaction disclosure for 4D Molecular Therapeutics, Inc.
Ticker impact
Officer/director Kirn David sold 1,922 shares of 4D Molecular Therapeutics on a 10b5-1 plan, disclosed via SEC Form 4.
Low near-term impact; any reaction is likely limited to sentiment/positioning rather than fundamentals.
The filing specifies an open-market sale under a pre-arranged Rule 10b5-1 plan, which typically reduces signal strength versus discretionary selling.
Market effects
Minimal; single-company insider transaction without accompanying operational/regulatory/drug-trial news.
None indicated.
None indicated.
Counterpoint
Because the sale is on a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations; any dip may be overdone.
Key entities
- issuer4D Molecular Therapeutics, Inc.
Subject of the SEC Form 4 insider sale disclosure.
- insiderKirn David
Officer/director who sold shares under a pre-arranged 10b5-1 plan.
